Island Pharmaceuticals (ASX:ILA) Days Payable : 0.00 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Island Pharmaceuticals Days Payable?

Island Pharmaceuticals's average Accounts Payable for the six months ended in Dec. 2023 was A$0.33 Mil. Island Pharmaceuticals's Cost of Goods Sold for the six months ended in Dec. 2023 was A$0.00 Mil.

The historical rank and industry rank for Island Pharmaceuticals's Days Payable or its related term are showing as below:

ASX:ILA's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 127.37
* Ranked among companies with meaningful Days Payable only.

Island Pharmaceuticals's Days Payable stayed the same from Dec. 2022 (0.00) to Dec. 2023 (0.00).

Island Pharmaceuticals Days Payable Historical Data

The historical data trend for Island Pharmaceuticals's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Island Pharmaceuticals Days Payable Chart

Island Pharmaceuticals Annual Data

Trend

Jun21

Jun22

Jun23

Jun24

Days Payable

Island Pharmaceuticals Semi-Annual Data
	Jun20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Days Payable	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of Island Pharmaceuticals's Days Payable

For the Biotechnology subindustry, Island Pharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Island Pharmaceuticals's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Island Pharmaceuticals's Days Payable distribution charts can be found below:

* The bar in red indicates where Island Pharmaceuticals's Days Payable falls into.

Island Pharmaceuticals Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Island Pharmaceuticals's Days Payable for the fiscal year that ended in Jun. 2024 is calculated as

	Days Payable (A: Jun. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Jun. 2023 )	+	Accounts Payable (A: Jun. 2024 ))	/	count )	/	Cost of Goods Sold (A: Jun. 2024 )	*	Days in Period
=	( (0.113	+	0.312)	/	2 )	/	0	*	365
=	0.2125					/	0	*	365
=	N/A

Island Pharmaceuticals's Days Payable for the quarter that ended in Dec. 2023 is calculated as:

	Days Payable (Q: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Jun. 2023 )	+	Accounts Payable (Q: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
=	( (0.113	+	0.554)	/	2 )	/	0	*	365 / 2
=	0.3335					/	0	*	365 / 2
=	N/A

Island Pharmaceuticals Days Payable Related Terms

Thank you for viewing the detailed overview of Island Pharmaceuticals's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Island Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Island Pharmaceuticals Ltd (ASX:ILA) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

c/- Bio101 Financial Advisory Pty Ltd, 697 Burke Road, Suite 201, Camberwell, Melbourne, VIC, AUS, 3124

Website

https://www.islandpharmaceuticals.com

Island Pharmaceuticals Ltd is a drug research and repurposing company focused on developing preventative or therapeutic drugs for viral infections. Its drug candidate ISLA-101 is a drug with a well-established safety profile, being repurposed for the prevention and treatment of dengue fever and another mosquito (or vector) borne diseases. The company carries out its research and development activities principally in the geographic regions of Australia and the United States of America.

Island Pharmaceuticals Headlines

No Headlines